Deliver Your News to the World

Clinical Study Demonstrates Viability of NeuraLightís Digital Biomarker Platform to Evaluate and Monitor Parkinsonís Disease Progression

The study reinforces the potential for oculometric measures to be used to assess and monitor Parkinsonís disease patients as a potential novel surrogate measure of disease progression


TEL AVIV & SAN FRANCISCO – WEBWIRE

A cross-sectional study led by Professor Ruth Djaldetti, renowned neurologist and expert in Parkinsonís disease and movement disorders and head of the Movement Disorders Center at Rabin Medical Center, presents the use of NeuraLightís oculometric measurement platform as an adjunct tool for clinical assessment in people with Parkinsonís disease.

Today, the clinical assessment of Parkinsonís disease (PD) severity relies primarily on the Movement Disorder Society-Sponsored Revision of the Unified Parkinsonís Disease Rating Scale (MDS-UPDRS) motor score (part III). Though widely accepted as the gold standard for PD rating, the subjective-in-nature scale has a high inter- and intra-rater variability that presents challenges for neurologists and researchers aiming to correctly assess disease status and progression and measure the effectiveness of novel disease-modifying therapeutics

Using proprietary computer vision and deep learning algorithms, NeuraLightís platform extracts dozens of oculometric measures (OMs)óeye movementsófrom standard web camera facial video and translates them into objective measurements of neurodegenerative disease. The benefit of evaluating eye movement abnormalities via OMs to assess various neurological disorders, including PD, has been studied extensively.

ďNeuraLightís technology enables us to assess the patientís neurological status in a sensitive and objective way,Ē shared Prof. Ruth Djaldetti, Head of the Movement Disorders Center in the neurological department, Rabin Medical Center, Israel. ďThe results of this study mark an important step on our path to knowing more about our Parkinsonís patientsí disease status, and we hope to continue our efforts to harness NeuraLightís platform in our clinical practice.Ē

Published in the Journal of Neural Transmission, the study, ďOculometric measures as a tool for assessment of clinical symptoms and severity of Parkinsonís disease,Ē examined 215 Parkinsonís patients with varying levels of disease severity using the MDS-UPDRS and NeuraLightís novel software-based platform. The main results of the study are:

  • Significant differences were found in multiple OMs between Parkinsonís patients and healthy controls, replicating previous research results that Parkinsonís disease has an effect on eye movements
  • Significant differences in OMs were found between patients with severe compared with mild to moderate disease, suggesting that these measures vary with stage of disease
  • Correlations between NeuraLightís oculometric test results and clinical assessment were found, presenting the potential to use this test as an adjunct tool for patientsí evaluation
  • The study reinforces the potential for OMs to be used to assess and monitor patients with Parkinsonís disease as a potential novel surrogate measure of disease progression


The publication of this study coincides with the initiation of NeuraLightís PALOMA (Parkinsonís Longitudinal Oculometric Measurement Assessment) trial, a first-of-its-kind, multi-center longitudinal study that will evaluate a planned cohort of 300 Parkinsonís patients using NeuraLightís oculometric platform.

The aim of the study is to demonstrate that NeuraLightís technology is able to detect patient deterioration faster than currently available subjective clinical rating scales, thereby allowing researchers and pharmaceutical manufacturers to run smaller, faster, less costly clinical trials. The study will additionally investigate novel prognostic indicators, which may enable innovative screening and precision-medicine applications for Parkinsonís disease. NeuraLight announced the first patient was enrolled and evaluated at the end of August.

To learn more about NeuraLightís technology or the studies outlined in this release, please visit: NeuraLight.ai/Technology.

About NeuraLight
NeuraLight is on a mission to transform the lives of billions of people impacted by neurological disorders by digitizing neurological evaluation and care. Its AI-driven platform integrates multiple digital markers to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders. The technology driving the platform includes proprietary deep learning algorithms which automatically extract a host of digital oculometric markers from facial videos captured with a standard webcam, supporting distributed trial design. NeuraLightís founders are repeat entrepreneurs and industry veterans leading a 35-strong team. The company is supported by renowned neurologists and two Nobel laureates as well as a stellar Scientific Advisory Board, and have raised over $30.5M to date.


( Press Release Image: https://photos.webwire.com/prmedia/42381/310907/310907-1.png )


WebWireID310907




 
 Neuralight
 Parkinsonís
 Clinical Study
 Ai
 Digital Biomarker


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.